JP2004527551A - エナンチオ純粋なエスシタロプラムの使用方法 - Google Patents
エナンチオ純粋なエスシタロプラムの使用方法 Download PDFInfo
- Publication number
- JP2004527551A JP2004527551A JP2002584912A JP2002584912A JP2004527551A JP 2004527551 A JP2004527551 A JP 2004527551A JP 2002584912 A JP2002584912 A JP 2002584912A JP 2002584912 A JP2002584912 A JP 2002584912A JP 2004527551 A JP2004527551 A JP 2004527551A
- Authority
- JP
- Japan
- Prior art keywords
- escitalopram
- treatment
- citalopram
- disorder
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 51
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 208000015238 neurotic disease Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 206010034912 Phobia Diseases 0.000 claims abstract description 4
- 208000019899 phobic disease Diseases 0.000 claims abstract description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 3
- 208000032841 Bulimia Diseases 0.000 claims abstract description 3
- 208000030814 Eating disease Diseases 0.000 claims abstract description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims abstract description 3
- 208000026345 acute stress disease Diseases 0.000 claims abstract description 3
- 208000022531 anorexia Diseases 0.000 claims abstract description 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 3
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 3
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 3
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 201000009032 substance abuse Diseases 0.000 claims abstract description 3
- 231100000736 substance abuse Toxicity 0.000 claims abstract description 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 15
- 229960001653 citalopram Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 7
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 238000011221 initial treatment Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 2
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract description 2
- 206010004716 Binge eating Diseases 0.000 abstract 1
- 208000014679 binge eating disease Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 208000019906 panic disease Diseases 0.000 description 6
- 206010041250 Social phobia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- 206010033664 Panic attack Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 101100309712 Arabidopsis thaliana SD11 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940066008 citalopram 20 mg Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940041201 escitalopram 10 mg Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100684 | 2001-05-01 | ||
| PCT/DK2002/000281 WO2002087566A1 (en) | 2001-05-01 | 2002-05-01 | The use of enantiomeric pure escitalopram |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527551A true JP2004527551A (ja) | 2004-09-09 |
| JP2004527551A5 JP2004527551A5 (enExample) | 2009-08-13 |
Family
ID=8160464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002584912A Pending JP2004527551A (ja) | 2001-05-01 | 2002-05-01 | エナンチオ純粋なエスシタロプラムの使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20040198809A1 (enExample) |
| EP (1) | EP1385503A1 (enExample) |
| JP (1) | JP2004527551A (enExample) |
| KR (2) | KR20100012089A (enExample) |
| CN (1) | CN1509169A (enExample) |
| AR (1) | AR033308A1 (enExample) |
| AT (1) | AT10974U1 (enExample) |
| BG (1) | BG108379A (enExample) |
| BR (1) | BR0208283A (enExample) |
| CA (1) | CA2445843A1 (enExample) |
| CZ (1) | CZ20033267A3 (enExample) |
| EA (1) | EA200301195A1 (enExample) |
| HR (1) | HRP20030744A2 (enExample) |
| HU (1) | HUP0400054A3 (enExample) |
| IL (1) | IL158031A0 (enExample) |
| IS (1) | IS6954A (enExample) |
| ME (1) | MEP5908A (enExample) |
| MX (1) | MXPA03008777A (enExample) |
| NO (1) | NO20034538D0 (enExample) |
| PL (1) | PL367480A1 (enExample) |
| SK (1) | SK14612003A3 (enExample) |
| UA (1) | UA82828C2 (enExample) |
| WO (1) | WO2002087566A1 (enExample) |
| YU (1) | YU85303A (enExample) |
| ZA (1) | ZA200307102B (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007526262A (ja) * | 2004-03-05 | 2007-09-13 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムオキサレートを含む結晶質調合物 |
| JP2009519969A (ja) * | 2005-12-14 | 2009-05-21 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムの放出調節製剤およびパルス型放出製剤 |
| WO2009096564A1 (ja) * | 2008-01-31 | 2009-08-06 | Takeda Pharmaceutical Company Limited | 注意欠陥・多動性障害の予防または治療剤 |
| JP2010535790A (ja) * | 2007-08-03 | 2010-11-25 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ | ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 |
| JP5404048B2 (ja) * | 2006-10-27 | 2014-01-29 | 久光製薬株式会社 | 貼付剤 |
| JP5740300B2 (ja) * | 2009-02-27 | 2015-06-24 | 久光製薬株式会社 | 経皮投与製剤 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| CZ20033267A3 (en) * | 2001-05-01 | 2004-06-16 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
| MXPA05005772A (es) * | 2002-12-23 | 2005-08-16 | Lundbeck & Co As H | Bromhidrato de escitalopram y un metodo para su preparacion. |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| US20050176680A1 (en) * | 2003-12-11 | 2005-08-11 | Sepracor, Inc. | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
| TWI347942B (en) * | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| JP2009511607A (ja) * | 2005-10-14 | 2009-03-19 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤 |
| US7569605B2 (en) * | 2005-10-14 | 2009-08-04 | Forest Laboratories Holdings Limited | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
| US8252336B2 (en) * | 2006-10-20 | 2012-08-28 | Ratiopharm Gmbh | Escitalopram and solid pharmaceutical composition comprising the same |
| EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
| ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
| US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| US10702512B2 (en) * | 2015-05-13 | 2020-07-07 | A. Carlsson Research Ab | Treatment of debilitating fatigue |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0236177A (ja) * | 1988-06-14 | 1990-02-06 | H Lundbeck As | 新規鏡像体及びその単離法 |
| WO2001003694A1 (en) * | 1999-07-08 | 2001-01-18 | H. Lundbeck A/S | Treatment of neurotic disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (enExample) * | 1965-03-18 | |||
| US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| ATE221522T1 (de) * | 1997-11-11 | 2002-08-15 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
| JP2002519321A (ja) * | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体 |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| WO2000023431A1 (en) * | 1998-10-20 | 2000-04-27 | H. Lundbeck A/S | Method for the preparation of citalopram |
| HK1048122B (zh) * | 1999-04-14 | 2005-01-14 | H‧隆德贝克有限公司 | 製備西酞普蘭的方法 |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| US6469064B2 (en) * | 2000-04-24 | 2002-10-22 | Aryx Therapeutics | Materials and methods for the treatment of depression |
| CZ20033267A3 (en) * | 2001-05-01 | 2004-06-16 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
-
2002
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0236177A (ja) * | 1988-06-14 | 1990-02-06 | H Lundbeck As | 新規鏡像体及びその単離法 |
| WO2001003694A1 (en) * | 1999-07-08 | 2001-01-18 | H. Lundbeck A/S | Treatment of neurotic disorders |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007526262A (ja) * | 2004-03-05 | 2007-09-13 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムオキサレートを含む結晶質調合物 |
| JP2009519969A (ja) * | 2005-12-14 | 2009-05-21 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムの放出調節製剤およびパルス型放出製剤 |
| JP5404048B2 (ja) * | 2006-10-27 | 2014-01-29 | 久光製薬株式会社 | 貼付剤 |
| JP2010535790A (ja) * | 2007-08-03 | 2010-11-25 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ | ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 |
| WO2009096564A1 (ja) * | 2008-01-31 | 2009-08-06 | Takeda Pharmaceutical Company Limited | 注意欠陥・多動性障害の予防または治療剤 |
| JP5740300B2 (ja) * | 2009-02-27 | 2015-06-24 | 久光製薬株式会社 | 経皮投与製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL158031A0 (en) | 2004-03-28 |
| BR0208283A (pt) | 2004-03-09 |
| US20040198811A1 (en) | 2004-10-07 |
| KR20040030609A (ko) | 2004-04-09 |
| EA200301195A1 (ru) | 2004-04-29 |
| IS6954A (is) | 2003-09-15 |
| UA82828C2 (en) | 2008-05-26 |
| US20080004338A1 (en) | 2008-01-03 |
| SK14612003A3 (sk) | 2004-04-06 |
| US20040192765A1 (en) | 2004-09-30 |
| HUP0400054A3 (en) | 2007-03-28 |
| WO2002087566A1 (en) | 2002-11-07 |
| NO20034538L (no) | 2003-10-09 |
| MXPA03008777A (es) | 2004-02-12 |
| PL367480A1 (en) | 2005-02-21 |
| AR033308A1 (es) | 2003-12-10 |
| NO20034538D0 (no) | 2003-10-09 |
| ZA200307102B (en) | 2004-09-13 |
| CN1509169A (zh) | 2004-06-30 |
| US20040198810A1 (en) | 2004-10-07 |
| CZ20033267A3 (en) | 2004-06-16 |
| BG108379A (bg) | 2004-11-30 |
| US20040198809A1 (en) | 2004-10-07 |
| HRP20030744A2 (en) | 2005-06-30 |
| KR20100012089A (ko) | 2010-02-05 |
| US20040192766A1 (en) | 2004-09-30 |
| US20040192764A1 (en) | 2004-09-30 |
| HUP0400054A2 (hu) | 2004-04-28 |
| EP1385503A1 (en) | 2004-02-04 |
| MEP5908A (xx) | 2010-02-10 |
| CA2445843A1 (en) | 2002-11-07 |
| AT10974U1 (de) | 2010-02-15 |
| YU85303A (sh) | 2006-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527551A (ja) | エナンチオ純粋なエスシタロプラムの使用方法 | |
| WO2004030633A2 (en) | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| JP2003504332A5 (enExample) | ||
| JP2007513052A (ja) | セロトニン再取り込み阻害剤およびアゴメラチンの併用。 | |
| JP2005513105A (ja) | 臨床的うつ病を治療するためのデオキシペガニンの使用 | |
| JP2024523876A (ja) | 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 | |
| AU2002254870A1 (en) | The use of enantiomeric pure escitalopram | |
| KR20010099648A (ko) | 신규 조성물 | |
| US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
| EA003546B1 (ru) | Новые способы лечения нервных расстройств | |
| AU2008201217A1 (en) | The use of enantiomeric pure escitalopram | |
| KR20020089399A (ko) | 세로토너직 계와 관련된 질병의 치료 | |
| HK1067047A (en) | The use of enantiomeric pure escitalopram | |
| JP2015515971A5 (enExample) | ||
| AU6378299A (en) | A new composition | |
| HRP20100463A2 (hr) | Upotreba čistog enantiomernog citaloprama | |
| CZ2004661A3 (cs) | Použití citalopramu pro léčení zvýšeného krevního tlaku | |
| WO2025219389A1 (fr) | Compositions contenant une combinaison synergique de mémantine et de vitamine d | |
| Dodd et al. | Duloxetine for major depression | |
| CN101495109A (zh) | 包含沙瑞度坦与5-羟色胺再摄取的选择性抑制剂或5-羟色胺/去甲肾上腺素的再摄取的抑制剂的联用的药物组合物 | |
| WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives | |
| HK1131885A (en) | Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination | |
| MXPA00010025A (en) | New treatments for nervous disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050422 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090403 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090410 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090624 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091006 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100519 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20101216 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101216 |